Aktuelle News
News Funktionen
Weitere Funktionen
20 September 2022
CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH: ROKOTE Laboratories licenses CEVEC’s CAP® Ad Technology for vaccine manufacturing
13 Juli 2022
CEVEC Pharmaceuticals GmbH
CEVEC’s license partner RZNOMICS Inc. receives approval to initiate clinical development of CAP® Ad Technology-produced gene therapy vector in liver cancer patients
7 September 2021
CEVEC Pharmaceuticals GmbH
CEVEC and UCB sign agreement for the use of CEVEC’s ELEVECTA(R) AAV manufacturing technology in Gene Therapy
27 Juli 2021
CEVEC Pharmaceuticals GmbH
CEVEC Pharmaceuticals GmbH: CEVEC closes growth financing round to serve strong demand in viral vector technologies for cell and gene therapies
2 Februar 2021
CEVEC Pharmaceuticals GmbH
CEVEC and CARISMA Therapeutics sign license agreement for the use of CAP(R) Technology in anti-tumor cell therapies
8 Januar 2021
CEVEC Pharmaceuticals GmbH
CEVEC announces new license agreement for its AAV manufacturing technology ELEVECTA(R) in gene therapy
10 November 2020
CEVEC Pharmaceuticals GmbH
CEVEC signs agreement with Roche for the use of CEVEC’s ELEVECTA(R) Technology in gene therapy
19 Oktober 2020
CEVEC Pharmaceuticals GmbH
CEVEC AND RZNOMICS SIGN LICENSE AGREEMENT FOR THE USE OF CAP(R) TECHNOLOGY IN MANUFACTURING OF ADENOVIRAL VECTORS
28 April 2020
CEVEC Pharmaceuticals GmbH
CEVEC Announces the Launch of the ELEVECTA(R) Platform – the Stable Producer Cell Line Technology for AAV Gene Therapy Vectors
16 April 2020
CEVEC Pharmaceuticals GmbH
CEVEC signs license agreement for the development and commercialization of exosomes for therapeutic use
19 Dezember 2019
CEVEC Pharmaceuticals GmbH
CEVEC and CellGenix announce the launch of GMP-grade TGF-ß1 for cell and gene therapy applications
16 April 2019
CEVEC Pharmaceuticals GmbH
CEVEC closes major financing round to further expand and commercialize its viral vector manufacturing platform
28 Juni 2018
CEVEC Pharmaceuticals GmbH
CEVEC strengthens its Scientific Advisory Board with the appointment of gene therapy specialist J. Fraser Wright, Ph.D.
8 Mai 2018
CEVEC Pharmaceuticals GmbH
CEVEC and CSL Limited sign exclusive license agreement for production of recombinant C1 Esterase Inhibitor using CEVEC’s proprietary CAP(R)Go technology
31 Januar 2018
CEVEC Pharmaceuticals GmbH
CEVEC and CellGenix cooperation leads to expansion of CellGenix cytokine portfolio with CAP(R)Go technology-derived TGF-ß1 for ex vivo cell culture
16 Januar 2018
CEVEC Pharmaceuticals GmbH
CEVEC to introduce new helper-free AAV packaging cell line for scalable stable gene therapy vector production at the Phacilitate Cell & Gene Therapy World Conference
14 November 2017
CEVEC Pharmaceuticals GmbH
CEVEC has been granted a new CAP(R)Go technology patent and reinforces its leading role in production of recombinant proteins previously out of reach
6 Juli 2017
CEVEC Pharmaceuticals GmbH
CEVEC licenses CAP(R)Go technology in the field of veterinary vaccines
11 Mai 2017
CEVEC Pharmaceuticals GmbH
CEVEC and PlasmidFactory announce collaboration regarding adeno-associated virus (AAV) production
16 März 2017
CEVEC Pharmaceuticals GmbH
CEVEC, medac and Provecs Medical enter into far-reaching adenoviral vector collaboration in oncology
9 Februar 2017
CEVEC Pharmaceuticals GmbH
CEVEC licenses CAP(R) technologies for the development and commercialization of vaccines against Zika Virus infections
27 Oktober 2016
CEVEC Pharmaceuticals GmbH
CEVEC submits Biologics Master File (BB-MF) for CAP(R) Technology to the U.S. FDA
29 Juni 2016
CEVEC Pharmaceuticals GmbH
CEVEC further strengthens organization to drive industrialization and commercialization of CAP(R) technologies
6 Juni 2016
CEVEC Pharmaceuticals GmbH
CEVEC und Paragon Bioservices beschließen umfangreiche Kooperation zum Roll-out der CAP(R) Technologien in Nordamerika
10 Mai 2016
CEVEC Pharmaceuticals GmbH
CEVECs CAP(R)GT setzt mit RCA-freier Produktion von adenoviralen Vektoren neuen Standard für Gentherapie-Anwendungen
22 Februar 2016
CEVEC Pharmaceuticals GmbH
CEVEC intensiviert ihre Marketing Aktivitäten und präsentiert auf verschiedenen angesehenen wissenschaftlichen Konferenzen in Europa und den USA
20 Januar 2016
CEVEC Pharmaceuticals GmbH
CEVEC und das City of Hope Beckman-Forschungsinstitut unterzeichnen Kooperations- und Lizenzvereinbarung für CEVEC’s proprietäre CAP(R)GT Technologie
28 Oktober 2015
CEVEC Pharmaceuticals GmbH
CEVEC und BioLamina kombinieren Technologieführerschaft für die kommerzielle Produktion rekombinanter Laminine für ex vivo-Zelltherapien
14 Oktober 2015
CEVEC Pharmaceuticals GmbH
CEVEC stärkt Team zur Umsetzung seiner starken Wachstumsstrategie
7 Oktober 2015
CEVEC Pharmaceuticals GmbH
CEVEC und CellGenix unterzeichnen Kooperations- und Lizenzvereinbarung für CEVECs unternehmenseigene CAP(R)Go Technologie